Toppublicaties

Colorectaal carcinoom

Geselecteerd door: Colorectaal carcinoom
  • juli 2023

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

  • Dasari A, Lonardi S, Garcia-Carbonero R, et al.
  • juni 2023

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

  • Bond MJG, Bolhuis K, Loosveld OJL, et al.
  • juni 2023

Global application of National Comprehensive Cancer Network resource-stratified guidelines for systemic treatment of colon cancer: a population-based, customisable model for cost, demand, and procurement

  • Wilson B E, Booth C M, Sullivan R, et al.
  • juni 2023

Urinary volatile organic compounds for colorectal cancer screening: A systematic review and meta-analysis

  • Van Liere ELSA, Van Dijk LJ, Bosch S, et al.
  • mei 2023

Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

  • Prager GW, Taieb J, Fakih M, et al.
  • mei 2023

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

  • Strickler JH, Cercek A, Siena S, et al.
  • mei 2023

Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial

  • Bahadoer RR, Hospers GAP, Marijnen CAM, et al.
  • april 2023

The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial

  • Bolhuis K, Bond MJG, Van Amerongen MJ, et al.
  • maart 2023

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

  • Van de Haar J, Ma X, Ooft SN, et al.
  • maart 2023

Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas

  • David J. Papke, Matthew B. Yurgelun, Amy E. Noffsinger
  • januari 2023

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

  • Kotani D, Oki E, Nakamura Y, et al.
  • januari 2023

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

  • Yaeger R, Weiss J, Pelster M S, et al.
Gedownload van https://medischeoncologie.nl/ op 11-12-2023 om 02:57. Copyright (C) 2023 BPM Medica.

Deel deze pagina